FDA fast track designation was granted for ETX-19477 in BRCA-mutated HR+/HER2– unresectable or metastatic breast cancer, ...
Agentic AI streamlines oncology decisions and trial matching, cutting admin load, flagging care gaps, and widening community ...
David Savage, MD, PhD, discusses the significance of abemaciclib's PFS benefit in liposarcoma and how he approaches getting ...
While the survival advantage seen among Asian American women with breast cancer isn't yet ready to shape clinical practice ...
During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead ...
FDA CBER Type C meeting will scrutinize statistical justification for pooled nonconcurrent published controls versus OST-400 ...
Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative ...
Hormone receptor and HER2 assessment remains the cornerstone for breast cancer subtyping and initial systemic therapy ...
Hearn Jay Cho, MD, PhD, discusses the ongoing role of the CoMMpass dataset in researching immunotherapy and targeted therapy in high-risk multiple myeloma. Hearn Jay Cho, MD, PhD, chief medical ...
PFS-6 reached 48.9% (95% CI, 26.3%-68.1%; P=.0047) by RANO 2.0 Kaplan-Meier estimation, exceeding the prespecified 20% standard-of-care benchmark. Survival outcomes ...
The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results